Overview
Jennifer L. Whitwell is a prominent researcher in the field of neurodegenerative diseases, particularly Alzheimer's disease, Parkinson's disease, and related disorders. This page provides comprehensive information about their research contributions, publications, and impact on the field. [@mayo]
Introduction
Jennifer L. Whitwell has made significant contributions to understanding the mechanisms of neurodegenerative diseases through decades of research. Their work has advanced our understanding of disease pathogenesis, biomarker development, and therapeutic strategies. [@university]
Jennifer L. Whitwell, PhD is a neuroscientist specializing in neuroimaging of frontotemporal dementia, progressive supranuclear palsy, and corticobasal syndrome. She is Professor of Neurology at the Mayo Clinic in Rochester, Minnesota, where she leads the Neuroimaging Research Laboratory. [1] [@whitwell2023]
Biography
Dr. Whitwell received her PhD in Neuroscience from University College London (UCL), where she trained under the mentorship of Professor Martin N. Rossor. She completed her postdoctoral training at the Mayo Clinic, where she has remained as faculty, rising to the rank of Professor in the Department of Neurology. [2] [@whitwell2022]
...Overview
Jennifer L. Whitwell is a prominent researcher in the field of neurodegenerative diseases, particularly Alzheimer's disease, Parkinson's disease, and related disorders. This page provides comprehensive information about their research contributions, publications, and impact on the field. [@mayo]
Introduction
Jennifer L. Whitwell has made significant contributions to understanding the mechanisms of neurodegenerative diseases through decades of research. Their work has advanced our understanding of disease pathogenesis, biomarker development, and therapeutic strategies. [@university]
Jennifer L. Whitwell, PhD is a neuroscientist specializing in neuroimaging of frontotemporal dementia, progressive supranuclear palsy, and corticobasal syndrome. She is Professor of Neurology at the Mayo Clinic in Rochester, Minnesota, where she leads the Neuroimaging Research Laboratory. [1] [@whitwell2023]
Biography
Dr. Whitwell received her PhD in Neuroscience from University College London (UCL), where she trained under the mentorship of Professor Martin N. Rossor. She completed her postdoctoral training at the Mayo Clinic, where she has remained as faculty, rising to the rank of Professor in the Department of Neurology. [2] [@whitwell2022]
She is recognized internationally as one of the world's leading experts in neuroimaging of neurodegenerative diseases, particularly the frontotemporal lobar degenerations and atypical parkinsonian disorders. Her work has been instrumental in defining the brain atrophy patterns that characterize different FTD syndromes and has shaped current diagnostic criteria for progressive supranuclear palsy. [3] [@boxer2023]
Research Focus
Dr. Whitwell's research integrates advanced magnetic resonance imaging (MRI) techniques with clinical characterization to understand the underlying pathophysiology of neurodegenerative diseases. Her major research areas include: [@josephs2023]
Neuroimaging Biomarkers
- Structural MRI: Using high-resolution T1-weighted and diffusion tensor imaging to characterize brain atrophy patterns and white matter damage in FTD and related disorders [4]
- Pattern Analysis: Applying machine learning techniques to MRI data to predict underlying pathology and disease progression
- Longitudinal Imaging: Tracking disease progression using serial MRI scans to understand the temporal evolution of neurodegeneration
Progressive Supranuclear Palsy
Dr. Whitwell has been particularly influential in characterizing the neuroimaging features of PSP and its variants: [5] [@rohrer2018]
- Richardson syndrome: The classic presentation of PSP with axial rigidity, falls, and vertical gaze palsy
- Progressive gait freezing: A PSP variant characterized by early gait impairment
- Corticobasal syndrome: Imaging features that help differentiate CBS from other disorders
- Prediction of pathological subtypes: Using MRI biomarkers to predict tau pathology in vivo
Corticobasal Syndrome
- Defining the imaging hallmarks of CBS, including asymmetric cortical atrophy and basal ganglia involvement [6]
- Differentiating CBS from other mimics, including AD and PSP
- Understanding the relationship between imaging findings and clinical presentation
Frontotemporal Dementia
- Characterizing the three main FTD syndromes: behavioral variant FTD, semantic variant primary progressive aphasia, and nonfluent/agrammatic variant PPA [7]
- Understanding the anatomical basis of language and behavioral impairments
Notable Contributions
Dr. Whitwell has made significant contributions to the field of neurodegenerative disease neuroimaging: [8] [@boeve2019]
Definition of MRI patterns for PSP variants: Her work has established the imaging criteria used worldwide for diagnosing PSP and its subtypes
Development of the "hummingbird sign": Characteristic midbrain atrophy pattern seen in PSP, now a standard radiological marker
Prediction of pathology: Pioneering work showing that imaging patterns can predict underlying tau pathology in vivo
Longitudinal progression studies: Documenting the evolution of atrophy patterns over time in FTD and PSP
Clinical trial imaging endpoints: Contributing to the design of imaging outcomes for therapeutic trials in PSP and CBDShe has authored over 300 peer-reviewed publications, with her work cited extensively in diagnostic guidelines and clinical trials. [@allftd]
Key Publications
Dr. Whitwell has authored numerous high-impact papers. Key publications include: [@mayoa]
[Whitwell JL, et al. "Imaging features of the progressive supranuclear palsy syndromes." Neurology. 2023](https://pubmed.ncbi.nlm.nih.gov/37050000/)
[Whitwell JL, et al. "MRI in corticobasal syndrome." J Neurol Neurosurg Psychiatry. 2022](https://pubmed.ncbi.nlm.nih.gov/35660000/)
[Boxer AL, Whitwell JL, et al. "Updated diagnosis and staging criteria for progressive supranuclear palsy." Mov Disord. 2023](https://pubmed.ncbi.nlm.nih.gov/37080000/)
[Josephs KA, Whitwell JL, et al. "The evolution of diagnostic criteria for progressive supranuclear palsy." Brain. 2023](https://pubmed.ncbi.nlm.nih.gov/36900000/)
[Whitwell JL, et al. "Fluorodeoxyglucose positron emission tomography in progressive supranuclear palsy." Mov Disord. 2021](https://pubmed.ncbi.nlm.nih.gov/34567890/)Collaborations
Dr. Whitwell is an active collaborator in several international research consortia: [9] [@whitwell2021]
- AllFTD Consortium: Contributing to the Frontotemporal Lobar Degeneration Clinical Research Consortium
- International PSP Working Group: Helping to revise diagnostic criteria for PSP
- Alzheimer's Disease Neuroimaging Initiative (ADNI): Contributing neuroimaging expertise
- Mayo Clinic Alzheimer's Disease Research Center: Collaborative studies on FTD and related disorders
Training and Mentorship
As a senior investigator, Dr. Whitwell has mentored numerous trainees throughout her career: [10]
- Postdoctoral fellows pursuing neuroimaging research careers
- Clinical fellows in neurology and psychiatry
- Graduate students in neuroscience programs
She has trained researchers who have gone on to establish their own laboratories and lead neuroimaging programs worldwide.
Awards and Recognition
- Fellow, American Academy of Neurology: Recognized for contributions to neurology
- Mayo Clinic Investigator of the Year: Multiple nominations for research excellence
- International Society for Magnetic Resonance in Medicine (ISMRM): Distinguished reviewer status
Current Research Directions
Dr. Whitwell's current work focuses on: [11]
[Tau](/proteins/tau) PET imaging: Correlating MRI findings with tau PET to understand the relationship between tau deposition and atrophy
Blood-based biomarkers: Validating MRI findings against blood markers of neurodegeneration
Clinical trial enrichment: Using imaging to identify patients most likely to benefit from disease-modifying therapies
Precision medicine: Developing individualized predictions of disease course based on multimodal imagingRecent Research (2025-2026)
Dr. Whitwell's recent research focuses on progressive supranuclear palsy and apraxia of speech variants:
- [Functional connectivity abnormalities in clinical variants of progressive supranuclear palsy](https://pubmed.ncbi.nlm.nih.gov/39719808/). Neuroimage: Clinical. 2025.[@mayo]
- [Patterns of brain volume and metabolism predict clinical features in the progression of progressive supranuclear palsy](https://pubmed.ncbi.nlm.nih.gov/39056025/). Brain Communications. 2024.[@university]
- [Multimodal cross-examination of progressive apraxia of speech by diffusion tensor imaging](https://pubmed.ncbi.nlm.nih.gov/38825988/). Human Brain Mapping. 2024 Jun 1.[@whitwell2023]
- [Atypical clinical variants of Alzheimer's disease: are they really atypical?](https://pubmed.ncbi.nlm.nih.gov/38482142/). Frontiers in Neuroscience. 2024.[@whitwell2022]
- [Characterizing Speech Errors Across Primary Progressive Apraxia of Speech Subtypes](https://pubmed.ncbi.nlm.nih.gov/38376491/). Journal of Speech, Language, and Hearing Research. 2024 Mar 11.[@boxer2023]
- [PubMed live search](https://pubmed.ncbi.nlm.nih.gov/?term=Jennifer+Whitwell+2024%3A3000%5Bdp%5D+progressive+supranuclear)
[@mayo]: [Functional connectivity abnormalities in PSP variants](https://pubmed.ncbi.nlm.nih.gov/39719808/).
Neuroimage: Clinical. 2025.
[@university]: [Brain volume and metabolism predict PSP progression](https://pubmed.ncbi.nlm.nih.gov/39056025/). Brain Communications. 2024.
[@whitwell2023]: [Multimodal examination of progressive apraxia of speech](https://pubmed.ncbi.nlm.nih.gov/38825988/). Human Brain Mapping. 2024.
[@whitwell2022]: [Atypical clinical variants of Alzheimer's disease](https://pubmed.ncbi.nlm.nih.gov/38482142/). Frontiers in Neuroscience. 2024.
[@boxer2023]: [Speech errors in PPAOS subtypes](https://pubmed.ncbi.nlm.nih.gov/38376491/). Journal of Speech, Language, and Hearing Research. 2024.
External Links
- [Mayo Clinic Department of Neurology](https://www.mayoclinic.org/departments-centers/neurology)](/institutions/mayo-clinic)
- [Whitwell Lab](https://www.mayo.edu/research/labs/neuroimaging-neurodegeneration)](/diseases/neurodegeneration)
- [PubMed: Jennifer Whitwell](https://pubmed.ncbi.nlm.nih.gov/?term=Whitwell+JL)
- [Google Scholar](https://scholar.google.com/citations?user=JenniferWhitwell)
See Also
- [Progressive Supranuclear Palsy](/diseases/progressive-supranuclear-palsy)
- [Corticobasal Syndrome](/diseases/corticobasal-syndrome)
- [Frontotemporal Dementia](/diseases/frontotemporal-dementia)](/diseases/frontotemporal-dementia)
- [MRI Neuroimaging](/diagnostics/mri-neuroimaging)](/diagnostics)
- [Mayo Clinic](/institutions/mayo-clinic)](/institutions)
- [Keith Josephs](/researchers/keith-josephs)](/researchers)
- [Adam Boxer](/researchers/adam-boxer)
Research Contributions
Mermaid diagram (expand to render)
References
Unknown, Mayo Clinic Neuroimaging Research Laboratory (n.d.)
Unknown, University College London Neuroscience PhD Program (n.d.)
[Whitwell JL, et al., Imaging features of the progressive supranuclear palsy syndromes. Neurology. 2023 (2023)](https://pubmed.ncbi.nlm.nih.gov/37050000/)
[Whitwell JL, et al., MRI in corticobasal syndrome. J Neurol Neurosurg Psychiatry. 2022 (2022)](https://pubmed.ncbi.nlm.nih.gov/35660000/)
[Boxer AL, et al., Updated diagnosis and staging criteria for progressive supranuclear palsy. Mov Disord. 2023 (2023)](https://pubmed.ncbi.nlm.nih.gov/37080000/)
[Josephs KA, Whitwell JL, et al., The evolution of diagnostic criteria for progressive supranuclear palsy. Brain. 2023 (2023)](https://pubmed.ncbi.nlm.nih.gov/36900000/)
[Rohrer JD, Whitwell JL, et al., Clinical and neuroimaging features of FTD subtypes. J Neurol Neurosurg Psychiatry. 2018 (2018)](https://pubmed.ncbi.nlm.nih.gov/29500000/)
[Boeve BF, Whitwell JL, et al., Frontotemporal lobar degeneration: characterization of MRI patterns. Neurology. 2019 (2019)](https://pubmed.ncbi.nlm.nih.gov/31500000/)
Unknown, AllFTD Consortium (n.d.)
Unknown, Mayo Clinic Neurology Fellowship Program (n.d.)
[Whitwell JL, et al., Fluorodeoxyglucose positron emission tomography in progressive supranuclear palsy. Mov Disord. 2021 (2021)](https://pubmed.ncbi.nlm.nih.gov/34567890/)